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Abstract
Background:  The first type III repeat of fibronectin is known to be involved in fibronectin matrix
assembly, and recombinant proteins from this type III repeat can inhibit cell proliferation, tumor
metastasis and angiogenesis. We have analyzed the way rat aortic smooth muscle cells (RASMCs)
interact with a recombinant protein encompassing a C-terminal portion of the first type III repeat
of fibronectin (protein III1-C).
Results:  Cells are able to adhere to and spread on III1-C coated on a dish. Both β 1 integrins and
cell surface heparan sulfate proteoglycans serve as receptors for III1-C. For example, cell
attachment to III1-C is partially inhibited by agents that block β 1 integrins or by heparin. Complete
inhibition of cell attachment is seen only when integrin blocking agents are combined with heparin.
Affinity chromatography revealed the binding of proteins that likely represent the integrin β 1 and
α 5 submits to a III1-C column. Cell adhesion to III1-C results in robust ERK1/2 activation that is
blocked by integrin-blocking agents. In addition, cell adhesion to III1-C and ERK1/2 activation by
III1-C are both inhibited by heparan sulfate but not by chondroitin sulfate. Moreover, heparitinase
treatment, but not chondroitinase treatment of RASMCs results in reduced cell adhesion and
ERK1/2 activation. Affinity chromatography experiments demonstrated that 35SO4-labeled cell
surface heparan sulfate proteoglycans bound specifically to III1-C.
Conclusions:  The results suggest that the 1st type III repeat of fibronectin contains a previously
unrecognized cell adhesion domain that stimulates robust ERK1/2 activation in RASMCs. Cells
interact with this domain through cell surface heparan sulfate proteoglycans and integrins, and both
classes of receptors are required for optimal cell adhesion and ERK1/2 activation.
Background
Fibronectin can control many aspects of cell behavior,
including cell growth, migration and differentiation [1].
Fibronectin exists in the blood as a dimer, but in tissues
it is in the form of an insoluble fibrillar matrix. The fibril-
lar form of fibronectin is thought to be the most relevant
form in vivo because this is the form with which most
cells interact [1]. Various lines of evidence suggest that
the fibrillar matrix form of fibronectin exerts effects on
cells that are not duplicated by the dimeric form of fi-
bronectin. For example, high concentrations of dimeric
fibronectin enhance cell migration whereas high concen-
trations of fibrillar fibronectin reduce cell migration [2].
Also, inhibition of fibronectin matrix assembly has been
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shown to inhibit cell growth in various systems [3–5].
These findings suggest that fibrillar fibronectin may
stimulate signal transduction pathways in cells that are
either not stimulated, or only marginally stimulated, by
dimeric fibronectin.
Fibronectin matrix assembly is a cell-mediated process
that requires the activity of integrins [1,6–8]. The in-
tegrin that is primarily responsible for assembling fi-
bronectin into the matrix is α 5β 1, although α vβ 3, α llbβ 3
and α 4β 1 can also function in this capacity [9–14]. In ad-
dition to integrins, fibronectin matrix assembly also de-
pends on self-association sites within fibronectin. For
example, the N-terminal 70 kDa region, the 1st type III
repeat and the 10th type III repeat are thought to be im-
portant for the proper alignment of fibronectin mole-
cules during matrix assembly [15–22]. We and others
have shown that a recombinant protein representing a
portion of the first type III repeat (protein III1-C) can af-
fect fibronectin matrix assembly and cell growth [2–
4,16]. Moreover, a mutant recombinant fibronectin mol-
ecule that is lacking the first seven type III repeats has
been shown to lead to defective fibronectin matrix as-
sembly in cell culture and in vivo, and to inhibition of cell
proliferation [23,24]. Although the matrix produced
with fibronectin lacking the first seven type III repeats
was somewhat aberrant, this study does show that some
matrix assembly can occur without the first type III re-
peat. Therefore, several approaches reveal that the fi-
bronectin type III repeats, and especially the first type III
repeat, play important roles in the regulation of fibronec-
tin matrix assembly and cell growth.
III1-C is known to inhibit cell proliferation [3,4]. Recent-
ly, III1-C (also known as anastellin) has been shown to
inhibit angiogenesis, and tumor growth and metastasis
[25]. In the present study we examine how cells interact
with and respond to III1-C, with a particular focus on sig-
naling through the Ras/ERK pathway. We find that cells
can adhere and spread on III1-C and that two classes of
receptors function in cell adhesion to III1-C; integrins
and cell-surface proteoglycans.
Results
Cell attachment and spreading on the first type III repeat 
of fibronectin
III1-C is a recombinant fibronectin fragment that en-
compasses most of the first type III repeat, but is missing
the A and B β -strands of the repeat [2]. We had previous-
ly found that III1-C inhibited the growth of normal dip-
loid smooth muscle cells (SMCs) in culture [4]. During
these experiments we noticed that the presence of III1-C
in the culture medium affected the morphology of cells at
early times after plating. As shown in Figure 1, cells plat-
ed onto fibronectin coated dishes attached and spread
well, typically containing numerous lamellipodia per cell
(Fig. 1A, panel FN). Cells seeded onto fibronectin coated
dishes with III1-C in the culture medium spread more
extensively and in a more circular pattern at early times
after plating than cells plated on fibronectin in the ab-
sence of III1-C (Fig. 1A, panels FN and FN+C, and Fig.
1B). Cells cultured on fibronectin for 4 hours show ap-
proximately the same extent of spreading as cells on fi-
bronectin plus III1-C (Fig. 1B), indicating that III1-C
accelerated the rate of spreading of the cells but did not
affect the eventual extent of spreading. The effect on cell
morphology was specific for III1-C because the negative
control protein III 11-C (a recombinant protein derived
from the 11th type III repeat in fibronectin, which, similar
to III1-C, is missing the A and B β -strands of this repeat)
had no effect on the morphology of the cells (Fig. 1A,
panel FN+11C, and Fig. 1B). Interestingly, the effect of
III1-C on cell morphology was seen even when the plates
had not been coated with fibronectin (Fig. 1A, panel C,
and Fig. 1B), indicating that intact fibronectin was not re-
quired for cell attachment and spreading when III1-C
was in the culture medium. Again, the negative control
protein III 11-C had no effect on cell morphology; cells
seeded onto uncoated plates with III 11-C in the culture
medium remained rounded and did not appreciably
spread over several hours (Fig. 1A, panel 11C, and Fig.
1B). These results indicated that III1-C had an effect on
the morphology of freshly plated cells. Moreover, the
plates did not need to be coated with any adhesive pro-
tein prior to seeding the cells with III1-C in the culture
medium, indicating that III1-C may have adsorbed onto
the tissue culture plastic and that cells then attached and
spread on the adsorbed III1-C.
To directly test whether cells were able to bind to III1-C
coated on a dish, various concentrations of either fi-
bronectin, III1-C or III 11-C were coated onto dishes and
cell attachment to these substrates was measured. As
shown in Figure 2, cells attach well to fibronectin and to
III1-C, but not to III 11-C coated on a dish. On a molar ba-
sis, III1-C was less effective at supporting cell attachment
than fibronectin, however, it was clear that RASMCs do
attach and spread well on III1-C coated on a dish. The
morphology of the cells seeded onto the III1-C–coated
wells was indistinguishable from the morphology shown
in Fig. 1A, panel C.
Role of integrins in cell attachment to III1-C
The attachment of RASMCs to III1-C was analyzed fur-
ther to determine the role played by integrins as poten-
tial adhesive receptors for III1-C. Various integrin-
blocking reagents were tested for their ability to block
RASMC attachment to III1-C and to fibronectin. The ad-
hesion of SMCs to fibronectin is mediated through β 1 in-
tegrins [1,26]. We confirmed these previous findings forBMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
Figure 1
Effect of III1-C on cell spreading. Panel A. RASMCs were plated onto either uncoated dishes (C and 11C panels) or
dishes coated with 20 µg/ml fibronectin (FN, FN+C and FN+11C panels) in the presence of either no recombinant protein in
the media (FN panel), or 25 µM III1-C (FN+C and C panels), or 25 µM III 11-C in the media (FN+11C and 11C panels). After
30 min at 37°C the cells were fixed, stained with coomassie blue and photographed under a light microscope. Bar equals 100
µm. Panel B. Quantitation of cell spreading over time in the culture conditions described for Panel A. Each data point is the
average of four samples; similar results were obtained from four independent experiments.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
our RASMCs, by showing a complete block of cell attach-
ment to fibronectin by EDTA (an agent that blocks all in-
tegrins), anti-β 1 blocking mAb, and RGD peptide, but
not by the negative control RAD peptide (Fig. 3A). Anti-
fibronectin antibodies also effectively blocked RASMC
attachment to fibronectin (Fig. 3A). Heparin did not in-
hibit cell attachment to fibronectin (Fig. 3A), however, it
did modestly reduce cell spreading on fibronectin (15%
inhibition of cell spreading, data not shown). These re-
sults indicate that RASMC adhesion to fibronectin is me-
diated by β 1 integrins.
Blocking studies indicated that cell attachment to III1-C
was partially mediated by β 1 integrins. For example,
RASMC attachment was partially blocked by EDTA, anti-
β 1 mAb, and RGD peptide (Fig. 3B), indicating the in-
volvement of integrins. However, cell attachment was
also partially blocked by heparin, which did not inhibit
cell attachment to fibronectin (Fig. 3A and 3B, Hep sam-
ples), indicating that a non-integrin receptor also medi-
ated cell attachment to III1-C. A complete block of cell
attachment to III1-C was only observed when heparin
was combined with integrin blocking agents; e.g.,
heparin + anti-β 1 mAb or heparin + RGD peptide (Fig.
3B). Anti-fibronectin antibodies modestly inhibited cell
attachment, but anti-III 1-C antibodies effectively
blocked cell attachment to III1-C (Fig. 3B). These results
demonstrate that cell attachment to III1-C was mediated
through both β 1 integrins and another class of receptors
on RASMCs.
One way in which integrins were originally shown to be
fibronectin receptors was by affinity chromatography of
radioiodinated cell surface proteins on a fibronectin col-
Figure 2
Cell attachment to III1-C. Fibronectin (), III1-C () or III 11-C () at various concentrations were coated onto plastic
wells. RASMCs were seeded onto the coated wells and the cells were allowed to adhere for 30 min at 37°C. The cells were
fixed, stained and the amount of cell attachment was measured. Each sample was performed in triplicate and the experiment
was done three times with comparable results each time.
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Figure 3
Blocking of cell attachment to III1-C RASMCs were seeded onto wells coated with either 20 µg/ml FN (top panel), or 25
µM III1-C (bottom panel) in the absence or presence of various inhibitors. The inhibitors were 100 µg/ml heparin (Hep), 10
mM EDTA (EDTA), 50 µg/ml anti-β 1 blocking mAb Ha2/5 (pi), 0.5 mg/ml GRGDSP peptide (RGD), 0.5 mg/ml GRADSP pep-
tide (RAD), 100 µg/ml anti-FN polyclonal antibody (anti-FN), and 60 µg/ml anti-IIIl-C polyclonal antibody (anti-C). After 30 min
at 37°C the cells were fixed, stained with crystal violet and the amount of cell attachment was measured. The dashed line indi-
cates the amount of signal seen on the negative control protein III 11-C, and represents the background A600 reading in these
experiments. Statistical analysis was done by Student's T-test (2-tailed); * p < .05, ** p < .005, *** p < .0005. Each sample was
done in quadruplicate and the experiment was performed three times with similar results each time.
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
N
o
 
B
l
o
c
k
H
e
p
E
D
T
A
H
e
p
+
E
D
T
A
ß
1
H
e
p
+
ß
1
R
G
D
R
A
D
H
e
p
+
R
G
D
a
n
t
i
-
F
N
a
n
t
i
-
C
FN
A
d
h
e
s
i
o
n
 
(
A
6
0
0
)
11C Control
*** *** *** ***
*** ***
***
*
0.000
0.100
0.200
0.300
0.400
0.500
0.600
N
o
 
B
l
o
c
k
H
e
p
E
D
T
A
H
e
p
+
E
D
T
A
ß
1
H
e
p
+
ß
1
R
G
D
R
A
D
H
e
p
+
R
G
D
a
n
t
i
-
F
N
a
n
t
i
-
C
III1-C
A
d
h
e
s
i
o
n
 
(
A
6
0
0
)
11C Control
***
*** ***
***
**
***
***
**
*BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
umn [27,28]. Consistent with these earlier studies, cell
surface radioiodination of RASMCs followed by affinity
chromatography on fibronectin Sepharose and elution
with EDTA revealed the binding of two major bands at
120 kDa and 140 kDa (Fig. 4,E lane under FN). These siz-
es match those of the β 1 and α 5 integrin submits, respec-
tively, that have been shown by affinity chromatography
to bind to the cell binding domain (i.e., 10th type III re-
peat) of fibronectin [27–31]. Affinity chromatography on
a III1-C Sepharose column revealed the binding of three
major bands of sizes 120 kDa, 140 kDa and 150 kDa (Fig.
4,E lane under C). The 120 kDa and 140 kDa bands likely
represent the β 1 and α 5 subunits (as above), while the
150 kDa band may represent either the α 2 or α 3 integrin
subunits, which are known to be expressed by VSMCs
[26]. Affinity chromatography on the control III 11-C col-
umn yielded no radioiodinated proteins that were eluted
from the column (Fig. 4,E lane under 11C). These results
are consistent with the hypothesis that one or more pi in-
tegrins act as receptors for III1-C. Taken together with
the integrin-blocking results described above, it is clear
that RASMC adhesion to III1-C is partially mediated
through β 1 integrins.
Cell adhesion to III1-C activates ERK1/2
Integrins are known to activate signaling pathways in
cells [32–35]. Among the most well-studied signaling
pathways is the Ras/MAPK pathway leading to activa-
tion of ERK1 and ERK2 [36]. We therefore decided to
test the effect of cell adhesion to III1-C on ERK activa-
tion. As expected, treatment of RASMCs with PDGF re-
sulted in activation of ERK1/2 (Fig. 5, PDGF lanes).
Plating RASMCs onto a fibronectin coated dish in the ab-
sence of growth factors yielded moderate activation of
ERK1/2, which peaked at 30 min then decreased some-
what over the next 30 min of the experiment (Fig. 5, bot-
tom panel). However, plating cells onto a III1-C coated
dish gave strong activation of ERK1/2, which peaked at
30 min and remained relatively constant for the subse-
quent 30 min (Fig. 5, top panel). The control protein III
11-C did not appreciably stimulate ERK1/2 phosphoryla-
tion (Fig. 5, 11C lanes, both panels). Thus, the adhesion
of RASMCs to III1-C resulted in robust activation of
ERK1/2 that was comparable to the activation obtained
with PDGF.
ERK activation by III1-C is dependent on β 1 integrins
As shown above, several agents that block β 1 integrin
function partially inhibit cell attachment to III1-C. We
therefore tested the effects of these agents on ERK1/2 ac-
tivation by III1-C. The results obtained with ERK1/2 ac-
tivation closely paralleled the results obtained with cell
attachment to III1-C, except that the individual blocking
agents were relatively more efficient at inhibiting ERK1/
2 activation. For example, heparin, EDTA, anti-β 1 mAb
and RGD peptide all significantly inhibited ERK1/2 acti-
vation by cell adhesion to III1-C (Fig. 6). Heparin was
most effective and completely blocked ERK1/2 activa-
tion. (Fig. 6). In contrast, the negative control RAD pep-
tide did not inhibit ERK1/2 activation by III1-C (Fig. 6,
C+RAD lane). These results indicate that both integrins
and the class of receptors inhibited by heparin were re-
quired for III1-C mediated activation of ERK1/2.
Role of heparan sulfate proteoglycans in cell adhesion to 
III1-C and ERK1/2 activation by III1-C
Because heparin was able to inhibit the attachment of
cells to III1-C and the activation of ERK1/2 by III1-C, we
tested the effect of other glycosaminoglycans on III1-C
stimulated ERK1/2 activity. Heparin, heparan sulfate
and dermatan sulfate blocked ERK1/2 activation by III1-
C (Fig. 7), and cell adhesion to III1-C (not shown). In
contrast, hyaluronic acid, chondroitin-4-sulfate and
chondroitin-6-sulfate had no effect on the ability of III1-
C to stimulate ERK1/2 activity (Fig. 7) or on the adhesion
of cells to III1-C (not shown). It is possible that heparin,
heparan sulfate and dermatan sulfate inhibit III1-C me-
diated cell adhesion and ERK1/2 activation due to com-
mon chemical features. For example, heparin, heparan
Figure 4
Affinity chromatography of 125I surface labeled pro-
teins on III1-C Sepharose RASMCs were surface labeled
with 125 I, lysed in octylglucoside lysis buffer, and these cell
lysates were passed over affinity columns containing either
FN (FN), III1-C (C), or III 11-C (11C). The columns were
washed and bound proteins were eluted with 10 mM EDTA
in lysis buffer. Samples from the final wash before elution (W
lanes), and from the elution (E lanes) fractions of each col-
umn were analyzed by SDS-PAGE and phosphorimager analy-
sis. Numbers to the left of the panel indicate the migration of
molecular mass markers (kDa). Asterisks mark the positions
of bands that bound to and were eluted from the FN and III1-
C columns.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
sulfate, and dermatan sulfate all contain iduronic acid
residues whereas chondroitin sulfate and hyaluronic
acid do not. The results presented above indicate that a
heparan sulfate proteoglycan (HSPG) or dermatan sul-
fate proteoglycan on the surface of RASMCs may serve as
a receptor for III1-C.
To further explore the possibility that a cell surface pro-
teoglycan serves as a receptor for III1-C, RASMCs were
treated with the glycosaminoglycan-degrading enzymes
seeded onto III1-C, and analyzed for the activation of
ERK1/2. Heparitinase treatment, but not chondroitinase
ABC treatment decreased the amount of ERK1/2 activa-
tion by III1-C (Fig. 8). Heparitinase treatment also inhib-
ited cell adhesion by 25–40%, while chondroitinase ABC
treatment did not inhibit cell adhesion to III1-C (not
shown). This result is consistent with the idea that
HSPGs but not chondroitin sulfate proteoglycans serve
as signaling receptors for III1-C.
Figure 5
Activation of ERK by cell adhesion to III1-C. RASMCs
were collected into DMEM + 0.5% BSA and either kept in
suspension in the absence (-) or presence of 2 ng/ml PDGF
(PDGF), or were seeded onto dishes precoated with either
20 µg/ml FN (FN), 25 µM III1-C (C), or 25 µM III 11-C
(11C). Note that the only cells that received growth factor
are the cells in the PDGF lane, which received the growth
factor 10 min before lysis. After 5, 15, 30, 45 or 60 min at
37°C the cells were lysed in sample buffer and analyzed by
inununoblotting with anti-phospho-p44/42 MAPK antibodies
(Phos-ERK panel). The blot was then stripped and reprobed
with anti-ERK antibodies (ERK panel) to analyze protein
loading. This experiment was done more than 3 times with
similar results each time.
Figure 6
Inhibition of III1-C mediated ERK activation by vari-
ous integrin inhibitors. RASMCs were collected in
DMEM+0.5% BSA and were then either left in suspension in
the absence (-) or presence of PDGF (PDGF), or plated onto
dishes precoated with either fibronectin (FN), III1-C (C and
C+... lanes), or III 11-C (11C), as described in the legend to
Fig. 5. Some samples of cells plated onto III1-C also contained
either 100 µg/ml heparin (C+Hep), 10 mM EDTA
(C+EDTA), 50 µg/ml anti-β 1 blocking mAb Ha2/5 (pi), 0.5
mg/ml GRGDSP peptide (RGD), 0.5 mg/ml GRADSP peptide
(RAD), or combinations of heparin plus integrin inhibitors, as
indicated. After 30 min at 37°C cells were lysed in SDS-
PAGE sample buffer and samples were analyzed by immunob-
lotting with anti-phospho-p44/42 MAPK antibodies (Phos-
ERK panels). Blots were then stripped and reprobed with
anti-ERK antibodies (ERK panels) to analyze protein loading.
The experiment was done 3 times with similar results each
time.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
To identify the cell surface proteoglycans that may serve
as receptors for III1-C, RASMCs were labeled with 35SO4
and cell lysates were applied to III1-C and III 11-C col-
umns. The most highly labeled band, migrating in a
smear at about 450 kDa, bound efficiently to the III1-C
column (Fig. 9A, compare flow through and elution
lanes). This proteoglycan resisted elution by 8 M urea
but was eluted by boiling the Sepharose beads in SDS
(Fig. 9A). This same proteoglycan did not bind apprecia-
bly to the III 11-C column (Fig. 9A). Heparitinase and
chondroitinase ABC treatment of the 35SO4 labeled sam-
ples revealed that the 450 kDa proteoglycan was com-
posed mostly of HSPGs (Fig. 9B). These results indicate
that most of the cell surface HSPGs of RASMCs can bind
to III1-C in affinity chromatography.
RASMC HSPGs were analyzed further by immunoblot-
ting with the monoclonal antibody 3G10 which specifi-
cally recognizes desaturated uronates on the heparan
sulfate stubs that remain associated with core proteins
after heparitinase digestion [37]. Complete digestion of
RASMC lysates with heparitinase reveals major bands at
46 kDa and 70 kDa, indicating that these are the sizes of
the major HSPG core proteins (not shown). RASMC
lysates were subjected to partial heparitinase treatment
(full digestion was not performed in order to allow some
GAGs to remain associated with the core proteins) then
applied to either III1-C or III 11-C Sepharose. As shown
in Fig. 10, most of the 46 kDa and 70 kDa HSPGs bound
to III1-C Sepharose but not to III 11-C Sepharose. In ad-
dition, the presence of heparin in the lysate inhibited the
46 kDa and 70 kDa HSPGs from binding to the III1-C
column (Fig. 10, compare C and C•H lanes). The inhibi-
tion of 46 kDa and 70 kDa binding to III1-C by heparin
suggests that these HSPGs may serve as receptors for
III1-C in cell adhesion and ERK1/2 signaling.
Discussion
We have found that cells can interact with a portion of
the fibronectin first type III repeat, leading to cell adhe-
sion and activation of ERK, and that this signaling re-
quires both cell surface HSPGs and integrins. RASMCs
are able to adhere to and spread on III1-C. Adhesion to
III1-C results in robust activation of ERK; comparable to
that seen with PDGF stimulation. Several independent
lines of evidence indicate that cell surface HSPGs and β 1
integrins act as receptors for III1-C and are required for
Figure 7
Inhibition of III1-C mediated ERK activation by gly-
cosaminoglycans. RASMCs were collected into DMEM +
0.5% BSA and either kept in suspension (-) or cells were
seeded onto dishes precoated with 25 µM III1-C (all other
lanes). Cells seeded onto III1-C contained either no gly-
cosaminoglycan in the medium (C) or 80 µg/ml heparin
(C+Hep), hyaluronic acid (C+HA), heparan sulfate (C+HS),
dermatan sulfate (C+DS), chondroitin-4-sulfate (C+C4S), or
chondroitin-6-sulfate (C+C6S). After 30 min at 37°C cells
were processed and analyzed by immunoblotting with anti-
phospho-p44/42 MAPK antibodies (Phos-ERK panel). The
blot was subsequently stripped and reprobed with anti-ERK
antibodies (ERK panel) as described in the legend to Fig. 5.
The experiment was done 3 times with similar results each
time.
Figure 8
Inhibition of III1-C mediated ERK activation by
heparitinase. RASMCs were collected in DMEM+0.5% BSA
and were then treated in suspension with either no GAGase
((-), PDGF, FN, C, Hep, and 11C samples) or with 0.1 u/ml of
heparitinase (H'ase), or 0.1 u/ml of chondroitinase ABC
(C'ase) for 1 hr at 37°C. Cells were then either left in sus-
pension in the absence (-) or presence of PDGF (PDGF) for
10 min, or cells were plated onto dishes precoated with
either fibronectin (FN), III1-C (C, Hep, H'ase, and C'ase
lanes), or III 11-C (11C). One sample of cells plated onto III1-
C contained 100 µg/ml heparin (Hep) in the medium. Cell
samples were analyzed by immunoblotting with anti-phos-
pho-p44/42 MAPK antibodies (Phos-ERK panel) followed by
anti-ERK antibodies (ERK panel) as described in the legend to
Fig. 5. The experiment was performed four times with similar
results each time.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
cell adhesion and ERK activation by III1-C. For example,
various β 1 integrin blocking agents inhibit cell attach-
ment to III1-C and ERK activation by III1-C. In addition,
inhibition by heparin, heparan-sulfate, and heparitinase,
but not by chondroitin sulfates or chondroitinase ABC all
point to the importance of HSPGs as receptors. Affinity
chromatography with 125I surface labeled proteins re-
sulted in the binding of proteins of the appropriate sizes
of β 1 integrins to both FN and III1-C columns. Moreover,
affinity chromatography with 35SO4-labeled cells sug-
gests that HSPGs with core protein sizes of 46 kDa and
70 kDa serve as III1-C receptors. Taken together, these
results indicate that the first type III repeat of fibronectin
can serve as a cell binding domain and that both in-
tegrins and cell surface HSPGs function as receptors for
this type III repeat.
Our results demonstrate that both integrins and cell sur-
face HSPGs are required for robust ERK 1/2 activation
when cells adhere to III1-C. These results are one of the
first demonstrations that HSPGs can activate the ERK
signaling pathway. Another example of this closely par-
allels our findings [38]. The adhesion of Jurkat T cells to
thrombospondin-1 has been shown to require the coop-
eration of three classes of receptors; β 1 integrins, CD47
and HSPGs [38]. Adhesion of the Jurkat T cells to throm-
bospondin-1 stimulates ERK1/2 activation and the bind-
ing of HSPGs to thrombospondin-1 is required for this
signaling. The particular HSPGs that mediate ERK1/2
activation in Jurkat T cells have not been identified, how-
ever, the authors speculate that syndecans may partici-
pate in the adhesion and signaling in that system [38].
This may also be the case in our system, as described be-
low.
Figure 9
Affinity chromatography of 35 SO4-labeled proteogly-
cans on III1-C Sepharose. Panel A. RASMCs were labeled
with 35SO4, which preferentially labels the glycosaminoglycan
chains of proteoglycans. Cells were lysed in NP40 buffer and
lysates were applied to either III1-C Sepharose (C lanes) or
III 11-C Sepharose (11C lanes) columns. The flow through
fractions were collected (Flow Thru lanes), the columns
were washed, and the bound material was eluted by first
applying 8 M urea elution buffer (Urea lanes), washing the
columns with PBS, then collecting the Sepharose beads and
boiling them in SDS-PAGE sample buffer (SDS lanes). The
lane labeled St shows a sample of the starting material. All
samples were separated on SDS-PAGE gels then detected by
phosphorimager analysis. Numbers to the left of the panel
indicate the migration of molecular mass markers (kDa).
Panel B. Samples of the starting material were treated with
either no enzyme ((-)), or with 0.03 u/ml chondroitinase
ABC (C'ase), or 0.03 u/ml heparitinase (H'ase), then analyzed
by SDS-PAGE and phosphorimager. The experiment was
performed twice with similar results both times.
Figure 10
Affinity chromatography HSPGs on III1-C Sepha-
rose. RASMCs were collected by trypsinization and lysed in
NP40 buffer. The lysate was then treated either without (-)
or with (+) 0.1 u/ml heparitinase for 1 hr at 37°C. Hepariti-
nase treated samples were then applied to either III1-C
Sepharose (lanes marked C) or III 11-C Sepharose (lanes
marked 11C). One sample was applied to a III1-C Sepharose
column in the presence of 0.5 mg/ml heparin (lanes marked
C•H). The flow through fractions were collected (FT lanes),
the columns were washed extensively, then the Sepharose
beads were collected and boiled in SDS-PAGE sample buffer
(Bound lanes). Samples were analyzed by immunoblotting
with the 3G10 antibody. Antibody 3G10 recognizes the uro-
nate stubs that remain associated with core proteins after
heparitinase digestion. Thus, after heparitinase digestion
3G10 shows the sizes of HSPG core proteins. Note that the
major HSPGs have core protein sizes of 46 kDa and 70 kDa,
and both of these HSPGs bind to the III1-C column but not
the III 11-C column. The experiment was performed twice
with similar results both times.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
One major family of cell surface HSPGs is the syndecan
family. There are 4 members in the syndecan family
(syndecan-1 through-4) [39,40]. Syndecan-1, -2 and -4
are known to bind to extracellular matrix proteins and
syndecan-1 and -4 have been shown to support stress fib-
er formation in conjunction with integrins [41–45]. The
HSPGs we have identified as III1-C receptors have core
proteins that migrate at the approximate sizes of synde-
can-1 (~69 kDa core protein) and syndecan-2 (~48 kDa
core protein) [40]. It is therefore possible that our 46
kDa and 70 kDa HSPGs represent syndecan family mem-
bers. As described above, the syndecans may cooperate
with β 1 integrins and CD47 to activate the ERK signaling
pathway in T cells [38]. A similar mechanism may apply
to the adhesion of RASMCs to III1-C. Future studies will
determine the identity of the HSPGs that act as III1-C re-
ceptors.
The Ras/MAPK pathway is typically thought to be a part
of a mitogenic pathway [36]. However, we and others
have shown that prolonged treatment with III1-C can in-
hibit cell proliferation [3,4], and here we show that cell
adhesion to III1-C can activate ERK1/2. One possible ex-
planation for this apparent discrepancy is that although
ERK1/2 are often involved in mitogenesis, in SMCs ERK
activation can lead to inhibition of proliferation [46].
This occurs through ERK-mediated stimulation of PGE2
production, which then inhibits the proliferation of
SMCs [46]. Further experiments will determine whether
RASMCs produce PGE2 after treatment with III1-C. An-
other possibility is that III1-C stimulates other signaling
pathways apart from the ERK pathway, and that one of
the other signaling pathways inhibits proliferation of the
cells. The relationship between ERK activation, stimula-
tion of other signaling pathways and growth inhibition
by III1-C will be elucidated by future experiments.
The III1-C protein has recently been shown to inhibit an-
giogenesis, tumor growth and metastasis [25]. Those
findings, along with our present findings reveal some in-
triguing parallels between III1-C and the angiogenesis
inhibitor endostatin [47]. For example, both III1-C and
endostatin are fragments of matrix proteins and can in-
hibit angiogenesis and tumor growth. In addition, recent
work has shown that cells interact with endostatin
through two classes of receptors; integrins and glypicans
(cell surface HSPGs) [48,49]. This parallels our findings
in this present report, that cells interact with III1-C
through integrins and cell surface HSPGs. Therefore,
III1-C and endostatin may inhibit angiogenesis through
related mechanisms involving both integrins and
HSPGs. Future work will determine the relative contri-
butions of these two classes of receptors in the biological
effects of III1-C.
Conclusions
We have found that cells can interact with the fibronectin
first type III repeat, leading to cell adhesion and activa-
tion of ERK, and that this signaling requires both cell
surface HSPGs and integrins. Results from various inde-
pendent types of experiments indicate that the first type
III repeat of fibronectin can serve as a cell binding do-
main and that both integrins and cell surface HSPGs
function as receptors for this type III repeat.
Materials and Methods
Materials
DMEM and glutamine Pen-Strep were obtained from
Life Technologies, Inc. FBS was purchased from Hy-
Clone Laboratories, Inc. Plasma fibronectin was purified
from human plasma by gelatin-agarose affinity chroma-
tography [50]. 4–20% gradient SDS-PAGE gels were
from Novex. Anti-phospho-p44/42 MAPK polyclonal
antibody and anti-p44/42 ERK polyclonal antibody were
purchased from New England Biolabs. Anti-β 1 blocking
antibody (Ha2/5) was from PharMingen. Peptides
GRGDSP and GRADSP were purchased from Life Tech-
nologies, Inc. Texas red and FITC labeled secondary an-
tibodies and 35SO4 were from ICN. Heparitinase,
chondroitinase ABC and mAb 3G10 were from Seika-
gaku. Anti-FN antibodies were a gift of Dr. Erkki Ruo-
slahti (Burnham Institute). ECL plus reagent and
Hyperfilm were obtained from Amersham. Complete™
protease inhibitor cocktail tablets were purchased from
Boehringer Mannheim Biochemicals. The expression
vector pQE-12 was obtained from Qiagen. Heparin and
all other chemicals were obtained from Sigma.
The purified glycosaminoglycans used in this study were
a generous gift of Dr. Nancy Schwartz (Univ. of Chicago).
The glycosaminoglycans were produced under a contract
from the National Institute of Arthritis and Musculoskel-
etal and Skin Diseases (NIH) and serve as reference
standards. The tissue sources of the glycosaminoglycans
were as follows: hyaluronic acid, human umbilical cord;
heparan sulfate, beef lung; dermatan sulfate, hog muco-
sa; chondroitin-4-sulfate, notochord from river sturgeon
(S. platorhynchus), and chondroitin-6-sulfate, cranial
cartilage of river sturgeon.
Cell culture
Primary rat aortic smooth muscle cells (RASMCs) were
isolated from 12–16 week old Sprague-Dawley rats as de-
scribed previously [51]. RASMCs were cultured in
DMEM supplemented with 10% FBS and glutamine Pen-
Strep. RASMCs were typically between passages 2 and 7
for experiments.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
Recombinant protein production
Proteins III1-C and III 11-C (previously called III11) were
produced in bacteria and purified as described previous-
ly [2]. III1-C encompasses fibronectin amino acids 600–
674 (Asn-Ala-Pro-Gln-...Thr-Ser-Thr-Pro), and III 11-C
amino acids 1,532–1,599 (Leu-Pro-Ser-Ser-...Thr-Ala-
Val-Thr), according to the previously published number-
ing method [52]. The recombinant proteins were ex-
pressed by the pQE-12 vector, which places a 6-His
coding sequence at the C-terminus of each protein. The
proteins were purified on Ni-agarose columns and were
> 9 8 %  p u r e  a s  j u d g e d  b y  S D S - P A G E  a n d  c o o m a s s i e
staining. Stock protein solutions were typically 700 µM
for III1-C and 520 µM for III 11-C in PBS.
Anti-III1-C antibodies were produced by immunizing
rabbits with III1-C. After one month the rabbits were
boosted and serum samples were collected every two
weeks. The rabbit serum was applied to an affinity col-
umn to purify the anti-III 1-C antibodies. In order to
avoid purifying antibodies to the 6-His tag in III1-C, the
affinity column was made with a GST fusion protein. The
1st type III repeat of fibronectin was expressed as a fusion
protein coupled to GST, and this GST-3FN1 fusion pro-
tein was coupled to Sepharose and used in affinity puri-
fication. Bound antibodies were eluted with 100 mM
triethylamine, pH 11.5 and the pH was neutralized with 1
M Tris, pH 8; (the antibody concentration was 0.4 mg/
ml). BSA (0.5 mg/ml) was added to stabilize the antibody
for subsequent handling. The antibody prep was dialyzed
extensively against PBS before use.
Cell attachment and spreading assays
For the cell spreading assay shown in Fig. 1, fibronectin
(20 µg/ml) was coated onto 24-well dishes for 1 hr at RT.
The wells were washed 3 times with PBS before adding
cells. Growing RASMCs were harvested by trypsinization
and collected into DMEM + 0.5% BSA + soybean trypsin
inhibitor. Cells were washed 3 times with DMEM + 0.5%
BSA, then resuspended at 1 ×  105 cells/ml in DMEM +
0.5% BSA, in the absence or presence of 25 µM III1-C or
25 µM III 11-C in the medium. Cells were seeded onto the
wells (0.5 ml/well, ~30% confluence), placed in a 37°C
incubator and allowed to adhere for either 7, 15, 30, 60,
120 or 240 min. Cells were then fixed with 3.7% parafor-
maldehyde, 60 mM sucrose in TBS, followed by staining
with Coomassie Blue dye (1 mg/ml Coomassie Brilliant
Blue, 45% MeOH, 10% acetic acid). Cells were destained
with water, air-dried, then photographed with a Leica
DM IRB phase microscope connected to a Polaroid CCD
camera and an Apple Macintosh computer for capturing
images. To quantitate the amount of spreading, each im-
age was analyzed with the NIH Image 1.61 application to
determine the total amount of area covered by cells and
this number was divided by the total number of cells in
the image to give an average area per cell (in pixels2/
cell).
Cell attachment assays shown in Fig. 2 and 3 were done
essentially as described previously [2]. Briefly, fibronec-
tin, III1-C or III 11-C at various concentrations were coat-
ed onto 96-well dishes for 1 hr at RT. The wells were then
washed 3 times with PBS before adding cells. Growing
RASMCs were harvested by trypsinization and collected
into DMEM + 0.5% BSA + soybean trypsin inhibitor.
Cells were washed 3 times with DMEM + 0.5% BSA, then
resuspended at 4 ×  105 cells/ml in DMEM + 0.5% BSA
with or without inhibitors, as indicated in the figures.
Cells were seeded onto the coated wells and allowed to
adhere for 30 min at 37°C. The cells were then fixed with
3.7% paraformaldehyde, 60 mM sucrose in TBS, fol-
lowed by 20% methanol, and staining in 0.5% crystal vi-
olet in 20% methanol. Stained cells were washed with
water and the dye was solubilized with 0.1 M sodium cit-
rate, pH 4.2, 50% ethanol. Attachment was quantitated
by measuring the absorbance at 600 nm.
125I cell surface labeling and affinity chromatography
The procedure was a modification of the procedure used
to isolate the fibronectin receptor and other integrins
[27,28]. The affinity resins were prepared by coupling fi-
bronectin, III1-C or III 11-C to CNBr-activated Sepharose
CL-4B according to the manufacturer's recommenda-
tions. The concentration of protein was typically 4–5 mg
fibronectin/ml of resin, or 8–10 mg protein/ml of resin
for III1-C and III 11-C. Ten 15-cm dishes of RASMCs
were washed twice with PBS, then harvested by detach-
ment of cells in PBS + 10 mM EDTA. The cells were
washed twice more with PBS, then resuspended at 4 ×
107 cells/ml in PBS. Cells were labeled with 1 mCi Na125I
and lactoperoxidase-H2O2, as previously described [27].
After labeling the cell pellet was washed with ice-cold
PBS + NaN3, then lysed in 2 volumes of OG Lysis Buffer
(200 mM octylglucoside, 1 mM CaCl2, 1 mM MgCl2, TBS,
PMSF) at 4°C. The lysate was spun at 14,000 ×  g for 15
min at 4°C, and the supernatant was used for affinity
chromatography. Lysate was applied to the affinity col-
umns (0.2 ml lysate was applied to 0.1 ml affinity matrix
bed volume), flow through fractions were collected and
passed over the columns twice more. Columns were
washed with 10 column volumes of Wash Buffer (40 mM
octylglucoside, 1 mM CaCl2, 1 mM MgCl2, TBS), before
elution of bound protein with 10 mM EDTA in Wash
Buffer. Samples from the final wash and eluted samples
were separated on 4–20% gradient Novex gels, the gels
were dried and exposed to phosphorimager cassette and
the radioactive signal was measured with a Storm phos-
phorimager instrument.BMC Cell Biology 2001, 2:18 http://www.biomedcentral.com/1471-2121/2/18
MAPK assay and immunoblotting
Wells of a 6-well plate were coated with either 20 µg/ml
fibronectin, 25 µM III1-C or 25 µM III 11-C for 1 hr at RT.
Wells were washed 3 times with PBS before adding cells.
Growing RASMCs were harvested by trypsinization and
collected into DMEM + 0.5% BSA + soybean trypsin in-
hibitor. Cells were washed 3 times with DMEM + 0.5%
BSA, then resuspended at 3 ×  105 cells/ml in DMEM +
0.5% BSA with or without integrin blocking agents or
other additions, as described in the figure legends. Cells
were either left in suspension (for suspended and PDGF
stimulated samples) or were seeded onto the coated
wells (1 ml per well) and allowed to adhere for 30 min at
37°C, or for the times indicated in the figure legend (Fig.
5). The cells stimulated with PDGF (2 ng/ml PDGF-BB)
received the growth factor 10 min before collecting the
cells for lysis, while the other samples received no growth
factor or serum. After the adhesion period plates were
placed on ice, unattached cells were collected and spun
down, while cell monolayers were washed once with ice
cold PBS then lysed with SDS-PAGE sample buffer (100
µl/well). Centrifuged pellets of unattached cells were
combined with the appropriate monolayer lysate sample
and the samples were heated to 100°C for 5 min. Samples
were separated on 4–20% gradient Novex gels, trans-
ferred to Immobilon P membranes, blocked with 5%
nonfat dry milk in TBS-Tween, then probed with anti-
phospho-p44/42 MAPK antibody according to the man-
ufacturer's recommendations. Blots were then stripped
in Stripping Buffer (2% SDS, 100 mM β -mercaptoetha-
nol, 62.5 mM Tris, pH 6.7) at 50°C for 30 min, washed 4
times with TBS-Tween, blocked with 5% nonfat dry milk
in TBS-Tween, then probed with anti-p44/42 ERK anti-
body according to the manufacturer's recommendations.
All blots were developed with the ECL plus reagent and
exposed to Hyperfilm. For both antibodies the typical ex-
posure times were under 5 min.
Heparitinase treatment of cells and lysates
6 well plates were coated with either fibronectin, III1-C
or III 11-C as described above. Growing RASMCs were
harvested by trypsinization and washed in DMEM + BSA
as described above. For GAGase treatment of intact cells,
the cells remained in suspension and received either no
enzyme or 0.1 u/ml heparitinase or 0.1 u/ml chondroiti-
nase ABC for 1 hr at 37°C with constant gentle rotation.
Cells were then plated onto precoated dishes and proc-
essed for immunoblotting with anti-phospho-p44/42
MAPK antibody as described above. Alternatively, after
heparitinase digestion cells were lysed directly in SDS
sample buffer and analyzed by immunoblotting with the
3G10 mAb (essentially as described above for anti-phos-
pho-p44/42 MAPK immunoblotting).
For GAGase treatment of cell lysates, cells were lysed on
ice in NP40 Lysis buffer (1% Nonidet P 40, 150 mM NaCl,
50 mM Tris, pH 8.0) plus protease inhibitors (Com-
plete™ protease inhibitor cocktail) at 2 ×  106 cells/ml.
Insoluble material was removed by centrifugation at
14,000 ×  g for 15 min at 4°C. Lysate was prepared for
heparitinase treatment by adding CaCl2 to 10 µM final
concentration. Heparitinase was added to 0.1 u/ml final
concentration and the lysate was incubated at 37°C for 1
hr. The lysate was then applied to affinity chromatogra-
phy columns as described below.
35SO4 labeling and affinity chromatography
Growing RASMCs labeled for 20 hr at 37°C with 200
µCi/ml 35S04 in DMEM + 10% dialyzed FCS + Pen-
Strep. Cells were placed on ice, washed once with PBS,
then lysed in NP40 Lysis buffer as described above. III1-
C and III 11-C columns were produced as described
above. Cell lysates were applied to III1-C or III 11-C col-
umns (typically 500 µl lysate was applied to 250 µl affin-
ity matrix bed volume), flow through fractions were
collected and passed over the columns twice more. The
final flow through fractions were then collected. Col-
umns were washed with 10 column volumes of NP40
Lysis buffer, then bound material was removed by boil-
ing the Sepharose beads in 2 column volumes of SDS
sample buffer. Alternatively, the bound material was
first eluted with 2 column volumes of 8 M urea buffer (8
M urea, 0.1 M NaH2PO4, 10 mM Tris, pH 8.0), followed
by washing with 10 column volumes of NP40 Lysis buff-
er, and then removing any remaining bound material by
boiling the Sepharose beads in SDS sample buffer. Sam-
ples were separated on 4–20% Novex SDS-PAGE gels,
the gels were fixed and dried and the radioactive material
was detected by using a phosphorimager.
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